Araclon Begins Phase 2 Trial of Vaccine for Alzheimer’s Disease

Araclon Begins Phase 2 Trial of Vaccine for Alzheimer’s Disease
Araclon Biotech is launching a Phase 2 clinical trial evaluating its active immunotherapy, or vaccine, ABvac40 for Alzheimer’s disease, after receiving approval from the Spanish Agency of Medicinal Products and Medical Devices. The multi-center trial will include 22 European clinical facilities (18 centers in Spain, two in France, one in Sweden and one in Italy). A total of 120 patients are estimated to be enrolled in the two-year trial, designed to confirm safety and tolerability data obtained in Phase 1 clinical studies of ABvac40 and to establish a dose regimen for the therapy. Of the 120 participants, some will not yet have developed symptoms of dementia — called prodromal patients — and some will have mild cognitive impairment (MCI). Half the participants will be given the active vaccine, ABvac40, and half will be given a placebo. These patients will be the control group. Enrollment is expected to begin in July. According to the World Health Organization (WHO), about 47 million people are suffering from dementia worldwide, with 60 to 70 percent of them attributed to Alzheimer’s disease. Experts anticipate that by 2050, there could be more than 132 million people globally with this type of dementia. Spain’s figures for the incidence of Alzheimer’s are similar to those seen in neighboring countries. According to a press release, the Spanish National Epidemiology Center point estimates that 7.3 percent of those living in Spain older than
Subscribe or to access all post and page content.


  1. kourosh says:

    Great job!
    I hope the Vaccine stop the progression of disease in patients who are already suffering from mild dementia.

  2. Doogie Howser says:

    we need a global commitment of the people to force the health community and Big Pharma along with their sponsored politicians to release those who are making improvements, than continuing to allow doctors to deny the disease any real rememdies.

Leave a Comment

Your email address will not be published. Required fields are marked *